Literature DB >> 33457034

Lithium-Associated Hypercalcemia Presenting with Neuropsychiatric Manifestations in a Patient with Bipolar Disorder.

Roukaya Benjelloun1, Imane Motaib1, Yassine Otheman2.   

Abstract

One of the overlooked adverse effects of lithium treatment is neuropsychiatric manifestations induced by hypercalcemia (LAH). Here, we present the case of a patient, with bipolar disorder under lithium, who presented with neuropsychiatric symptoms that revealed hyperparathyroidism-induced hypercalcemia. This case illustrates the importance of monitoring parathyroid function and calcium levels in patients under lithium, especially in premenopaused women. LAH may mimic symptoms of manic episodes and should be sought in the case of brutal onset of confusion, anxiety, and/or hallucinations in the course of a bipolar disorder.
Copyright © 2020 Roukaya Benjelloun et al.

Entities:  

Year:  2020        PMID: 33457034      PMCID: PMC7787858          DOI: 10.1155/2020/6630838

Source DB:  PubMed          Journal:  Case Rep Psychiatry        ISSN: 2090-6838


  10 in total

1.  Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism.

Authors:  C Joborn; J Hetta; F Niklasson; J Rastad; L Wide; H Agren; G Akerström; S Ljunghall
Journal:  Psychoneuroendocrinology       Date:  1991       Impact factor: 4.905

2.  Hypercalcemia and "primary" hyperparathyroidism during lithium therapy.

Authors:  Howard I Shapiro; Karina A Davis
Journal:  Am J Psychiatry       Date:  2015-01       Impact factor: 18.112

Review 3.  Lithium toxicity profile: a systematic review and meta-analysis.

Authors:  Rebecca F McKnight; Marc Adida; Katie Budge; Sarah Stockton; Guy M Goodwin; John R Geddes
Journal:  Lancet       Date:  2012-01-20       Impact factor: 79.321

4.  Hypothyroidism and hyperparathyroidism associated with lithium.

Authors:  P E Garfinkel; C Ezrin; H C Stancer
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

5.  Alterations in parathyroid dynamics in lithium-treated subjects.

Authors:  S T Haden; A L Stoll; S McCormick; J Scott
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

6.  Lithium-induced alterations in parathyroid cell function: insight into the pathogenesis of lithium-associated hyperparathyroidism.

Authors:  F Racke; C R McHenry; D Wentworth
Journal:  Am J Surg       Date:  1994-11       Impact factor: 2.565

7.  Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study.

Authors:  Umberto Albert; David De Cori; Andrea Aguglia; Francesca Barbaro; Fabio Lanfranco; Filippo Bogetto; Giuseppe Maina
Journal:  J Affect Disord       Date:  2013-07-17       Impact factor: 4.839

8.  The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.

Authors:  Felicity Ng; Oommen K Mammen; Ingeborg Wilting; Gary S Sachs; I Nicol Ferrier; Frederick Cassidy; Serge Beaulieu; Lakshmi N Yatham; Michael Berk
Journal:  Bipolar Disord       Date:  2009-09       Impact factor: 6.744

9.  Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy.

Authors:  Samir S Awad; Judiann Miskulin; Norman Thompson
Journal:  World J Surg       Date:  2003-04       Impact factor: 3.352

10.  Lithium-induced Hyperparathyroidism and Hypercalcemia.

Authors:  Srikanth Naramala; Hussain Dalal; Sreedhar Adapa; Amir Hassan; Venu Madhav Konala
Journal:  Cureus       Date:  2019-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.